Herbal granules aim to stop AFib recurrence after heart procedure

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-80 years (inclusive); * Diagnosed with non-valvular persistent atrial fibrillation, having failed at least one antiarrhythmic drug treatment, and scheduled to undergo initial ablation; * Voluntarily participate in this study and sign an informed consent form. If the subject is unable to read or sign the informed consent form due to reasons such as lack of capacity, the informed consent process must be completed and signed by their legal guardian. If the subject is unable to read the informed consent form (e.g., illiterate subjects), the informed consent process must be witnessed and signed by a witness. Exclusion Criteria: * Valvular atrial fibrillation or paroxysmal atrial fibrillation * NYHA functional class IV or LVEF \<40%, LA diameter \>55mm; * Moderate to severe left ventricular hypertrophy (wall thickness \>1.5cm); * Patients with acute coronary syndrome or requiring stent implantation * Patients with a history of cardiac surgery within the past 6 months or previous catheter ablation * Duration of atrial fibrillation ≥5 years; * Hyperthyroidism; * Patients with atrial fibrillation and cardiomyopathy; * Patients with bradyarrhythmia requiring pacemaker implantation * Known bleeding diathesis, presence of left atrial/left atrial appendage thrombus, or severe hemostasis and coagulation dysfunction * Severe hepatic or renal insufficiency ALT ≥3 × ULN or eGFR \<45 ml/min/1.73 m²; * Patients allergic to the components of the study drug; * Patients who are currently participating or have participated in other interventional clinical studies within the past 3 months. * Pregnant or lactating women, or those with an expected lifespan of \<12 months; * Other vulnerable groups, excluding the elderly/illiterate individuals, including those with mental illnesses, cognitive impairments, critically ill patients, etc * Any other reasons deemed by the investigator as unsuitable for the patient's participation in this study